Allergy Therapeutics has announced the results of
clinical trials that tested out a hay fever vaccine and found the results to be
The study to test out the vaccine involved over 1,000
patients n the U.S., Canada and Europe. Overall there was a 13 to 27 percent
improvement in the patients using the vaccine as compared to a placebo.
"Proof of efficacy and safety of Pollinex Quattro in
this grass study is a breakthrough for allergy sufferers," said lead
researcher Professor Tony Frew, Professor of Allergy and Respiratory Medicine
at the Brighton and Sussex Medical School. "Patients showed significant
and clinically meaningful improvement."
The Pollinex Quattro
injection is given four times in three weeks before the pollen season starts.